Inhibition of Kaposi's Sarcoma in Vivo by Fenretinide

Clinical Cancer Research

Volumn 9, Issue 16, 2003, Pages 6020-6029

  Ferrari, Nicoletta ^a   Morini, Monica ^b   Pfeffer, Ulrich ^a   Minghelli, Simona ^c   Noonan, Douglas M ^b   Albini, Adriana ^a  

^a Laboratory of Oncology   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c ADVANCED BIOTECHNOLOGY CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; FENRETINIDE; GELATINASE A; MATRIGEL; MESSENGER RNA; PROTEIN; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR BETA; RETINOID; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER INVASION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MODEL; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME RELEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; KAPOSI SARCOMA; MALE; MATRIGEL PLUG ASSAY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; RANDOMIZATION; RECURRENCE RISK; RNA ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CELL MOVEMENT; COLLAGEN; DRUG COMBINATIONS; ENDOTHELIUM, VASCULAR; FENRETINIDE; HUMANS; LAMININ; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; PROTEOGLYCANS; SARCOMA, KAPOSI; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 0347995044     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Chang, Y., Cesarman, E., Pessin, M. S., Lee, F., Culpepper, J., Knowles, D. M., and Moore, P. S. Identification of Herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science (Wash. DC), 266: 1865-1869, 1994.
2. Gallo, R. C. The enigmas of Kaposi's sarcoma. Science (Wash. DC), 282: 1837-1839, 1998.
3. Chokunonga, E., Levy, L. M., Bassett, M. T., Mauchaza, B. G., Thomas, D. B., and Parkin, D. M. Cancer incidence in the African population of Harare, Zimbabwe: second results from the cancer registry 1993–1995. Int. J. Cancer, 85: 54-59, 2000.
4. Thompson, E., Nakamura, S., Shima, T., Melchiori, A., Martin, G., Salahuddin, S., Gallo, R., and Albini, A. Supernatants of acquired immunodeficiency syndrome-related Kaposi's sarcoma cells induce endothelial cell chemotaxis and invasiveness. Cancer Res., 51: 2670-2676, 1991.
5. Albini, A., Fontanini, G., Masiello, L., Tacchetti, C., Bigini, D., Luzzi, P., Noonan, D. M., and Stetler-Stevenson, W. G. Angiogenic potential in vivo by Kaposi sarcoma cell-free supernatants and HIV1-tat product: inhibition of KS-like lesions by TIMP-2. AIDS, 8: 1237-1244, 1994.
6. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 285: 1182-1186, 1971.
7. Kerbel, R. S. Tumor angiogenesis: past, present and the near future. Carcinogenesis (Lond.), 21: 505-515, 2000.
8. Tosetti, F., Ferrari, N., De Flora, S., and Albini, A. ‘Angioprevention’: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J., 16: 2-14, 2002.
9. Hong, W. K., and Lippman, S. M. Cancer chemoprevention. J. Natl. Cancer Inst. Monogr., 17: 49-53, 1995.
10. Lippman, S. M., and Lotan, R. Advances in the development of retinoids as chemopreventive agents. J. Nutr., 130: 479S-482S, 2000.
11. Lippman, S. M., Lee, J. J., Karp, D. D., Vokes, E. E., Benner, S. E., Goodman, G. E., Khuri, F. R., Marks, R., Winn, R. J., Fry, W., Graziano, S. L., Gandara, D. R., Okawara, G., Woodhouse, C. L., Williams, B., Perez, C., Kim, H. W., Lotan, R., Roth, J. A., and Hong, W. K. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J. Natl. Cancer Inst., 93: 605-618, 2001.
12. Corbeil, J., Rapaport, E., Richman, D. D., and Looney, D. J. Antiproliferative effect of retinoid compounds on Kaposi's sarcoma cells. J. Clin. Investig., 93: 1981-1986, 1994.
13. Gill, P. S., Espina, B. M., Moudgil, T., Kidane, S., Esplin, J. A., Tulpule, A., and Levine, A. M. All-trans retinoic acid for the treatment of AIDS-related Kaposi's sarcoma: results of a pilot Phase II study. Leukemia, 8: S26-S32, 1994.
14. Miles, S. A., Dezube, B. J., Lee, J. Y., Krown, S. E., Fletcher, M. A., Saville, M. W., Kaplan, L., Groopman, J., Scadden, D. T., Cooley, T., Von Roenn, J., and Friedman-Kien, A. Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma. AIDS, 16: 421-429, 2002.
15. Hong, W. K., Lippman, S. M., Itri, L. M., Karp, D. D., Lee, J. S., Byers, R. M., Schantz, S. P., Kramer, A. M., Lotan, R., Peters, L. J., et al. Prevention of second primary tumors with isotretinoin in squamouscell carcinoma of the head and neck. N. Engl. J. Med., 323: 795-801, 1990.
16. Moon, R. C., Thompson, H. J., Becci, P. J., Grubbs, C. J., Gander, R. J., Newton, D. L., Smith, J. M., Phillips, S. L., Henderson, W. R., Mullen, L. T., Brown, C. C., and Sporn, M. B. N-(4-Hydroxyphenyl-)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res., 39: 1339-1346, 1979.
17. Veronesi, U., De Palo, G., Marubini, E., Costa, A., Formelli, F., Mariani, L., Decensi, A., Camerini, T., Del Turco, M. R., Di Mauro, M. G., Muraca, M. G., Del Vecchio, M., Pinto, C., D’Aiuto, G., Boni, C., Campa, T., Magni, A., Miceli, R., Perloff, M., Malone, W. F., and Sporn, M. B. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J. Natl. Cancer Inst., 91: 1847-1856, 1999.
18. Holmgren, L., O’Reilly, M. S., and Folkman, J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med., 1: 149-153, 1995.
19. Lotan, R., Amos, B., Watanabe, H., and Raz, A. Suppression of melanoma cell motility factor receptor expression by retinoic acid. Cancer Res., 52: 4878-4884, 1992.
20. Majewski, S., Marczak, M., Szmurlo, A., Jablonska, S., and Bollag, W. Retinoids, interferon α,1,25-dihydroxyvitamin D3 and their combination inhibit angiogenesis induced by non-HPV-harboring tumor cell lines. RAR α mediates the antiangiogenic effect of retinoids. Cancer Lett., 89: 117-124, 1995.
21. Lingen, M. W., Polverini, P. J., and Bouck, N. P. Retinoic acid induces cells cultured from oral squamous cell carcinomas to become anti-angiogenic. Am. J. Pathol., 149: 247-258, 1996.
22. Lingen, M. W., Polverini, P. J., and Bouck, N. P. Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells. Lab. Investig., 74: 476-483, 1996.
23. Iurlaro, M., Benelli, R., Masiello, L., Rosso, M., and Albini, A. β Interferon inhibits HIV-1 Tat induced angiogenesis; synergism with 13-cis retinoic acid. Eur. J. Cancer, 34: 570-576, 1998.
24. Pienta, K. J., Nguyen, N. M., and Lehr, J. E. Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. Cancer Res., 53: 224-226, 1993.
25. Ribatti, D., Alessandri, G., Baronio, M., Raffaghello, L., Cosimo, E., Marimpietri, D., Montaldo, P. G., De Falco, G., Caruso, A., Vacca, A., and Ponzoni, M. Inhibition of neuroblastoma-induced angiogenesis by fenretinide. Int. J. Cancer, 94: 314-321, 2001.
26. Umesono, K., Murakami, K. K., Thompson, C. C., and Evans, R. M. Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors. Cell, 65: 1255-1266, 1991.
27. Zhou, X. F., Shen, X. Q., and Shemshedini, L. Ligand-activated retinoic acid receptor inhibits AP-1 transactivation by disrupting c-Jun/c-Fos dimerization. Mol. Endocrinol., 13: 276-285, 1999.
28. Albini, A., Paglieri, I., Orengo, G., Carlone, S., Aluigi, M. G., DeMarchi, R., Matteucci, C., Mantovani, A., Carozzi, F., Donini, S., and Benelli, R. The β-core fragment of human chorionic gonadotrophin (hCG) inhibits growth of Kaposi's sarcoma-derived cells and a new immortalized Kaposi's sarcoma cell line. AIDS, 11: 713-721, 1997.
29. Albini, A., Iwamoto, Y., Kleinman, H. K., Martin, G. R., Aaronson, S. A., Kozlowski, J. M., and McEwan, R. N. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res., 47: 3239-3245, 1987.
30. Albini, A., D’Agostini, F., Giunciuglio, D., Paglieri, I., Balansky, R. M., and De Flora, S. Inhibition of invasion, gelatinase activity, tumor take and metastasis of malignant cells by N-acetylcysteine. Int. J. Cancer, 61: 121-129, 1995.
31. Ferrari, N., Vidali, G., and Pfeffer, U. Use of quantitative polymerase chain reaction to study retinoid receptor expression. Methods Enzymol., 282: 48–64, 1997.
32. Muller, P. Y., Janovjak, H., Miserez, A. R., and Dobbie, Z. Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques, 32: 1372–1374, 1376, 1378-1379, 2002.
33. Liu, G., Wu, M., Levi, G., and Ferrari, N. Inhibition of cancer cell growth by all-trans retinoic acid and its analog N-(4-hydroxyphenyl) retinamide: a possible mechanism of action via regulation of retinoid receptors expression. Int. J. Cancer, 78: 248-254, 1998.
34. Guruswamy, S., Lightfoot, S., Gold, M. A., Hassan, R., Berlin, K. D., Ivey, R. T., and Benbrook, D. M. Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma. J. Natl. Cancer Inst., 93: 516-525, 2001.
35. Folkman, J., Watson, K., Ingber, D., and Hanahan, D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature (Lond.), 339: 58-61, 1989.
36. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996.
37. Giavazzi, R., Giuliani, R., Coltrini, D., Bani, M. R., Ferri, C., Sennino, B., Tosatti, M. P., Stoppacciaro, A., and Presta, M. Modulation of tumor angiogenesis by conditional expression of fibroblast growth factor-2 affects early but not established tumors. Cancer Res., 61: 309-317, 2001.
38. Bergers, G., Javaherian, K., Lo, K. M., Folkman, J., and Hanahan, D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science (Wash. DC), 284: 808-812, 1999.
39. Erdreich-Epstein, A., Tran, L. B., Bowman, N. N., Wang, H., Cabot, M. C., Durden, D. L., Vlckova, J., Reynolds, C. P., Stins, M. F., Groshen, S., and Millard, M. Ceramide signaling in fenretinide-induced endothelial cell apoptosis. J. Biol. Chem., 277: 49531-49537, 2002.
40. Reynolds, C. P., and Lemons, R. S. Retinoid therapy of childhood cancer. Hematol. Oncol. Clin. North Am., 15: 867-910, 2001.
41. Hultin, T. A., McCormick, D. L., May, C. M., and Moon, R. C. Effects of pretreatment with the retinoid N-(4-hydroxyphenyl)-all-transretinamide and phenobarbital on the disposition and metabolism of N-(4-hydroxyphenyl)-all-trans-retinamide in mice. Drug Metab. Dispos., 16: 783-788, 1988.
42. Formelli, F., Clerici, M., Campa, T., Di Mauro, M. G., Magni, A., Mascotti, G., Moglia, D., De Palo, G., Costa, A., and Veronesi, U. Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J. Clin. Oncol., 11: 2036-2042, 1993.
43. Vaccari, M., Silingardi, P., Argnani, A., Horn, W., Giungi, M., Mascolo, M. G., Grilli, S., and Colacci, A. In vitro effects of fenretinide on cell-matrix interactions. Anticancer Res., 20: 3059-3066, 2000.
44. Coussens, L. M., and Werb, Z. Inflammation and cancer. Nature (Lond.), 420: 860-867, 2002.
45. Saaristo, A., Karpanen, T., and Alitalo, K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene, 19: 6122-6129, 2000.
46. Cornali, E., Zietz, C., Benelli, R., Weninger, W., Masiello, L., Breier, G., Tschachler, E., Albini, A., and Stürzl, M. Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma. Am. J. Pathol., 149: 1851-1869, 1996.
47. Masood, R., Cai, J., Zheng, T., Smith, D. L., Naidu, Y., and Gill, P. S. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc. Natl. Acad. Sci. USA, 94: 979-984, 1997.
48. Diaz, B. V., Lenoir, M. C., Ladoux, A., Frelin, C., Demarchez, M., and Michel, S. Regulation of vascular endothelial growth factor expression in human keratinocytes by retinoids. J. Biol. Chem., 275: 642-650, 2000.
49. Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'shea, K. S., Powell-Braxton, L., Hillan, K. J., and Moore, M. W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature (Lond.), 380: 439-442, 1996.
50. Gunningham, S. P., Currie, M. J., Han, C., Robinson, B. A., Scott, P. A., Harris, A. L., and Fox, S. B. VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis. J. Pathol., 193: 325-332, 2001.
51. Waltenberger, J., Claesson-Welsh, L., Siegbahn, A., Shibuya, M., and Heldin, C. H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem., 269: 26988-26995, 1994.
52. Hamada, K., Oike, Y., Takakura, N., Ito, Y., Jussila, L., Dumont, D. J., Alitalo, K., and Suda, T. VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis. Blood, 96: 3793-3800, 2000.
53. Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. The nuclear receptor superfamily: the second decade. Cell, 83: 835-839, 1995.
54. Pergolizzi, R., Appierto, V., Crosti, M., Cavadini, E., Cleris, L., Guffanti, A., and Formelli, F. Role of retinoic acid receptor overexpression in sensitivity to fenretinide and tumorigenicity of human ovarian carcinoma cells. Int. J. Cancer, 81: 829-834, 1999.
55. Chakravarti, D., LaMorte, V. J., Nelson, M. C., Nakajima, T., Schulman, I. G., Juguilon, H., Montminy, M., and Evans, R. M. Role of CBP/P300 in nuclear receptor signalling. Nature (Lond.), 383: 99-103, 1996.
56. Bannister, A. J., Oehler, T., Wilhelm, D., Angel, P., and Kouzarides, T. Stimulation of c-Jun activity by CBP: c-Jun residues Ser63/73 are required for CBP induced stimulation in vivo and CBP binding in vitro. Oncogene, 11: 2509-2514, 1995.
57. Illi, B., Puri, P., Morgante, L., Capogrossi, M. C., and Gaetano, C. UltraRapid communication: nuclear factor-βB and cAMP response element binding protein mediate opposite transcriptional effects on the Flk-1/KDR gene promoter. Circ. Res., 86: 1273-1281, 2000.